A population-based cohort study emulating a goal trial estimated the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in contrast with sodium-glucose cotransporter-2 (SGLT-2) inhibitors on the danger for gastroesophageal reflux illness (GERD) and its problems in sufferers with kind 2 diabetes.
The study discovered that the incidence of GERD and its problems was greater amongst GLP-1 RA customers, and the danger of GERD-related problems was greater for people who smoke, sufferers with weight problems, and sufferers with gastric-related comorbidities. The outcomes are published in Annals of Internal Medicine.
Researchers from McGill University and Lady Davis Institute, Jewish General Hospital in Montreal used the U.Okay. Clinical Practice Research Datalink to create a goal trial emulation framework that evaluated the danger for GERD and its problems in sufferers aged 18 years or older with kind 2 diabetes initiating GLP-1 RAs or SGLT-2 inhibitors.
The study included 24,708 new customers of GLP-1 RAs who had a median follow-up of three years and 89,096 new customers of SGLT-2 inhibitors who had a median follow-up of two.7 years. The major final result was a analysis of GERD and the secondary final result was problems of GERD. The researchers discovered that in follow-up the incidence price for GERD was 7.9 per 1,000 individual years. 138 whole problems of GERD had been noticed, with greater than 90% of them being Barrett esophagus.
At three-year follow-up, the danger ratio (RR) was 1.27 for GERD and 1.55 for GERD problems in GLP-1 RA customers in contrast with SGLT-2 inhibitor customers. Secondary analyses discovered that dangers for GERD had been greater total for every GLP-1 RA kind besides lixisenatide, and dangers for GERD problems had been greater in ever-smokers, sufferers with weight problems, and sufferers with gastric comorbidities.
The outcomes counsel the danger for GERD and its problems is greater amongst sufferers with kind 2 diabetes utilizing GLP-1 RAs versus SGLT-2 inhibitors. Clinicians and sufferers ought to concentrate on the potential adversarial impact of GLP-1 RAs on GERD.
More data:
Yunha Noh et al, Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes, Annals of Internal Medicine (2025). DOI: 10.7326/ANNALS-24-03420
Citation:
Diabetes sufferers on Ozempic-like medicine extra prone to develop gastroesophageal reflux illness ( 15)
16
diabetes-patients-ozempic-drugs-gastroesophageal.html
The content material is supplied for data functions solely.